Published in Drug Metab Dispos on January 13, 2005
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol (2008) 1.85
Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet (2009) 1.77
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 1.54
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol (2008) 1.53
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol (2008) 1.36
Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol (2011) 1.30
Maraviroc: a review of its use in HIV infection and beyond. Drug Des Devel Ther (2015) 1.29
Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother (2012) 1.14
HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis. J Virol (2014) 1.14
Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol (2009) 1.06
Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol (2008) 1.05
Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04
CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers. Drug Metab Dispos (2014) 0.98
Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J Clin Pharmacol (2014) 0.95
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol (2008) 0.89
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression. Antimicrob Agents Chemother (2013) 0.89
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma. Clin Chim Acta (2014) 0.86
Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc. Drug Metab Dispos (2012) 0.84
Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. Clin Med Ther (2009) 0.83
Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. J Virol (2013) 0.82
Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. Br J Clin Pharmacol (2009) 0.80
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. J Control Release (2015) 0.78
Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert Opin Drug Metab Toxicol (2014) 0.75
Maraviroc: the evidence for its potential in the management of HIV. Core Evid (2007) 0.75
The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1. Front Immunol (2017) 0.75
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos (2004) 3.00
Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol (2002) 2.16
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol (2008) 1.85
Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica (2011) 1.57
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 1.54
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol (2008) 1.53
Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Discov Today (2004) 1.49
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov (2011) 1.45
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev (2007) 1.42
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br J Clin Pharmacol (2008) 1.14
Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br J Clin Pharmacol (2008) 1.14
The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther (2003) 1.09
Keynote review: Is declining innovation in the pharmaceutical industry a myth? Drug Discov Today (2005) 1.09
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials. Antimicrob Agents Chemother (2011) 1.07
P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol (2010) 0.96
Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc. J Acquir Immune Defic Syndr (2010) 0.94
Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos (2010) 0.94
A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. Br J Clin Pharmacol (2008) 0.89
Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharm (2010) 0.89
Pharmacokinetics, pharmacodynamics, and safety of the 5-HT(1B/1D) agonist eletriptan following intravenous and oral administration. J Clin Pharmacol (2002) 0.87
The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. Kidney Int (2004) 0.85
Pharmaceutical R&D in the spotlight: why is there still unmet medical need? Drug Discov Today (2007) 0.85
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol (2009) 0.81
Linking toxicity and chemistry: think globally, but act locally? Curr Opin Drug Discov Devel (2004) 0.81
The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols. Bioanalysis (2011) 0.81
Which metabolites circulate? Drug Metab Dispos (2013) 0.80
The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol (2008) 0.79
Communicating the risks and benefits of medicines. Drug Discov Today (2007) 0.79
Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel (2009) 0.79
R&D technology investments: misguided and expensive or a better way to discover medicines? Drug Discov Today (2006) 0.78
A review of the clinical pharmacology of maraviroc. Introduction. Br J Clin Pharmacol (2008) 0.78
The time to move cytochrome p450 induction into mainstream pharmacology is long overdue. Drug Metab Dispos (2007) 0.77
Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol Lett (2008) 0.77
Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. J Pharm Sci (2012) 0.77
Will biomedical innovation change the future of healthcare? Drug Discov Today (2009) 0.76
Commentary on variability in vitamin K antagonist metabolism. Expert Opin Drug Metab Toxicol (2006) 0.75
The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol (2002) 0.75
Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations. Drug Metab Dispos (2004) 0.75
Does validation stagnate innovation? Bioanalysis (2010) 0.75
Are predictive biomarkers of toxicity worth having? An economic model. Xenobiotica (2011) 0.75
Biomarkers: the pièce de résistance of innovative medicines. Curr Opin Drug Discov Devel (2007) 0.75
Editorial overview: safety of drugs can never be absolute. Curr Opin Drug Discov Devel (2006) 0.75
Dogma driven science, the need to establish a common base line. Chem Biol Interact (2008) 0.75
Characterization of ABC transporters in human skin. Drug Metabol Drug Interact (2014) 0.75
Immunomodulatory therapies and the risk of opportunistic infections. Curr Opin Drug Discov Devel (2010) 0.75
Editorial overview: safety/toxicity threshold concepts in drug discovery and development. Curr Opin Drug Discov Devel (2005) 0.75
Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference. Bioorg Med Chem Lett (2005) 0.75
Discovery, innovation and the cyclical nature of the pharmaceutical business. Drug Discov Today (2002) 0.75
Pharmacogenomics and adverse drug reactions; prospective screening for risk identification. Curr Opin Drug Discov Devel (2009) 0.75
Ethnic variation in drug response: implications for the development and regulation of drugs. Curr Opin Drug Discov Devel (2008) 0.75
Should scientific innovation be managed? Drug Discov Today (2002) 0.75